• Alias: TOCA 511
    • A replication-competent retroviral vector, derived from the Moloney murine leukemia virus, encoding a modified form of the yeast suicide gene CD (Toca 511) that will enter and transfect tumor cells and express CT, an enzyme that catalyzes the intracellular conversion of the prodrug flucytosine (5-FC) into the antineoplastic agent 5-FU
    • Phase 2/3 in combination with lomustine, temozolomide, or bevacizumab in recurrent high-grade glioma; phase 1/2 combination with Toca FC as intralesional, intratumoral, or intravenous infusion in solid tumor or lymphoma patients
    • Phase 1/2 dose: Toca 511 dose ranged m 1.4 × 10
    Other topics in Targeted and Immunotherapy Agents